Philippe Gabriel Steg

Learn More
Kristian Thygesen; Joseph S. Alpert; Harvey D. White; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction TASK FORCE MEMBERS Chairpersons: Kristian Thygesen (Denmark)*, Joseph S. Alpert (USA)*, Harvey D. White (New Zealand)* Biomarker Group: Allan S. Jaffe, Coordinator (USA), Fred S. Apple (USA), Marcello Galvani(More)
Task Force Members: Gilles Montalescot* (Chairperson) (France), Udo Sechtem* (Chairperson) (Germany), Stephan Achenbach (Germany), Felicita Andreotti (Italy), Chris Arden (UK), Andrzej Budaj (Poland), Raffaele Bugiardini (Italy), Filippo Crea (Italy), Thomas Cuisset (France), Carlo Di Mario (UK), J. Rafael Ferreira (Portugal), Bernard J. Gersh (USA), Anselm(More)
BACKGROUND Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation. METHODS AND RESULTS The Academic Research Consortium is an informal collaboration between academic research organizations in the(More)
Authors/Task Force Members: Frans Van de Werf, Chairperson (Belgium)*, Jeroen Bax (The Netherlands), Amadeo Betriu (Spain), Carina Blomstrom-Lundqvist (Sweden), Filippo Crea (Italy), Volkmar Falk (Germany), Gerasimos Filippatos (Greece), Keith Fox (UK), Kurt Huber (Austria), Adnan Kastrati (Germany), Annika Rosengren (Sweden), P. Gabriel Steg (France),(More)
BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them(More)
BACKGROUND Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug. The effect of these determinants on clinical outcomes after an acute myocardial infarction is unknown. METHODS We consecutively enrolled 2208 patients presenting with an acute myocardial infarction(More)
BACKGROUND Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. METHODS We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin(More)
BACKGROUND B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension. METHODS We conducted a prospective study of 1586 patients who came to the emergency department with acute dyspnea and whose B-type natriuretic peptide was measured with a bedside assay. The clinical diagnosis of congestive heart failure was(More)
Authors/Task Force Members: Marco Roffi* (Chairperson) (Switzerland), Carlo Patrono * (Co-Chairperson) (Italy), Jean-Philippe Collet† (France), Christian Mueller† (Switzerland), Marco Valgimigli† (The Netherlands), Felicita Andreotti (Italy), Jeroen J. Bax (The Netherlands), Michael A. Borger (Germany), Carlos Brotons (Spain), Derek P. Chew (Australia),(More)
Roxana Mehran, MD; Sunil V. Rao, MD; Deepak L. Bhatt, MD, MPH; C. Michael Gibson, MS, MD; Adriano Caixeta, MD, PhD; John Eikelboom, MD, MBBS; Sanjay Kaul, MD; Stephen D. Wiviott, MD; Venu Menon, MD; Eugenia Nikolsky, MD, PhD; Victor Serebruany, MD, PhD; Marco Valgimigli, MD, PhD; Pascal Vranckx, MD; David Taggart, MD, PhD; Joseph F. Sabik, MD; Donald E.(More)